

# Fourth Contrast Study: contrast study for patients undergoing diagnostic coronary angiography

<b>Submission date</b> 12/09/2003	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 12/09/2003	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
<b>Last Edited</b> 15/04/2016	<b>Condition category</b> Surgery	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Mr YKS Viswanath

**Contact details**  
The James Cook University Hospital  
Marton Road  
Middlesbrough  
United Kingdom  
TS4 3BW  
+44 (0)1642 854863  
yks.viswanath@stees.nhs.uk

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**  
N0227115061

# Study information

## Scientific Title

Fourth Contrast Study: contrast study for patients undergoing diagnostic coronary angiography

## Study objectives

To compare two contrast agents routinely used in the Cath Lab.

To assess the clinical outcomes and adverse effects of these two agents.

To assess the potential advantage of one over the other.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Not provided at time of registration

## Study design

Randomised controlled trial

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Hospital

## Study type(s)

Diagnostic

## Participant information sheet

## Health condition(s) or problem(s) studied

Angiography

## Interventions

Randomised study of two commonly used contrast agents (NIOPAM and Xenetix). Reactions due to contrast reaction will be recorded in a data collection form which will form the basis for a computer database. Will abide by The Data Protection Act.

## Intervention Type

Drug

## Phase

Not Specified

## Drug/device/biological/vaccine name(s)

NIOPAM®, Xenetix®

**Primary outcome measure**

Clinical outcome and adverse effects of the contrast agents.

**Secondary outcome measures**

Not provided at time of registration

**Overall study start date**

01/08/2002

**Completion date**

30/09/2003

## Eligibility

**Key inclusion criteria**

1. Patients admitted for cardiac catheterisation.
2. Approximately 2000 subjects.
3. No selection bias to gender or age group.

**Participant type(s)**

Patient

**Age group**

Other

**Sex**

Both

**Target number of participants**

2000

**Key exclusion criteria**

Pregnant patients will be excluded, unless patient has life threatening condition.

**Date of first enrolment**

01/08/2002

**Date of final enrolment**

30/09/2003

## Locations

**Countries of recruitment**

England

United Kingdom

**Study participating centre**

**The James Cook University Hospital**  
Middlesbrough  
United Kingdom  
TS4 3BW

## **Sponsor information**

### **Organisation**

Department of Health (UK)

### **Sponsor details**

Richmond House  
79 Whitehall  
London  
United Kingdom  
SW1A 2NL

### **Sponsor type**

Government

### **Website**

<http://www.doh.gov.uk>

## **Funder(s)**

### **Funder type**

Hospital/treatment centre

### **Funder Name**

South Tees Hospitals NHS Trust (UK)

## **Results and Publications**

### **Publication and dissemination plan**

Not provided at time of registration

### **Intention to publish date**

### **Individual participant data (IPD) sharing plan**

### **IPD sharing plan summary**

Not provided at time of registration